Decision

Advertising investigations: May 2020

Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.

Documents

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Contact [email protected] if you have concerns with the advertising of medicines or write to:

Advertising Standards Unit,
10 South Colonnade
Canary Wharf
London
E14 4PU

Alternatively, contact the pharmaceutical self-regulatory bodies, the for advertising for over the counter medicines, or the for advertisements to health professionals for prescription medicines.

See the Blue Guide for guidance on how medicines should be promoted or advertised in the UK.

Updates to this page

Published 15 June 2020

Sign up for emails or print this page